Symptoms of overdose include numbness, tingling, pain, and cyanosis of the extremities associated with diminished or absent peripheral pulses; respiratory depression; an increase and/or decrease in blood pressure, usually in that order; confusion, delirium, convulsions, and coma; and/or some degree of nausea, vomiting, and abdominal pain.L38469 In case of overdose, warmth should be applied to affected areas and vasodilators administered. Local poison control centres should be contacted for detailed information on care in cases of ergot overdose.
A 9,10alpha-dihydro derivative of ergotamine. Dihydroergotamine is used as an abortive therapy for migraines.L38469 Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile.
Recent improvements have been made in the design of intranasal delivery devices allowing for greater delivery of dihydroergotamine solution to the vasculature-rich upper nasal cavity.A239569 The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution formulated at 75% of the strength of the existing intranasal product.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Modafinil | The metabolism of Dihydroergotamine can be increased when combined with Modafinil. |
| Armodafinil | The metabolism of Dihydroergotamine can be increased when combined with Armodafinil. |
| Valsartan | Dihydroergotamine may decrease the antihypertensive activities of Valsartan. |
| Ramipril | Dihydroergotamine may decrease the antihypertensive activities of Ramipril. |
| Remikiren | Dihydroergotamine may decrease the antihypertensive activities of Remikiren. |
| Torasemide | Dihydroergotamine may decrease the antihypertensive activities of Torasemide. |
| Guanadrel | Dihydroergotamine may decrease the antihypertensive activities of Guanadrel. |
| Olmesartan | Dihydroergotamine may decrease the antihypertensive activities of Olmesartan. |
| Chlorthalidone | Dihydroergotamine may decrease the antihypertensive activities of Chlorthalidone. |
| Nitroprusside | Dihydroergotamine may decrease the antihypertensive activities of Nitroprusside. |
| Minoxidil | Dihydroergotamine may decrease the antihypertensive activities of Minoxidil. |
| Treprostinil | Dihydroergotamine may decrease the antihypertensive activities of Treprostinil. |
| Bendroflumethiazide | Dihydroergotamine may decrease the antihypertensive activities of Bendroflumethiazide. |
| Fosinopril | Dihydroergotamine may decrease the antihypertensive activities of Fosinopril. |
| Trandolapril | Dihydroergotamine may decrease the antihypertensive activities of Trandolapril. |
| Metolazone | Dihydroergotamine may decrease the antihypertensive activities of Metolazone. |
| Benazepril | Dihydroergotamine may decrease the antihypertensive activities of Benazepril. |
| Cyclothiazide | Dihydroergotamine may decrease the antihypertensive activities of Cyclothiazide. |
| Candoxatril | Dihydroergotamine may decrease the antihypertensive activities of Candoxatril. |
| Mecamylamine | Dihydroergotamine may decrease the antihypertensive activities of Mecamylamine. |
| Moexipril | Dihydroergotamine may decrease the antihypertensive activities of Moexipril. |
| Lisinopril | Dihydroergotamine may decrease the antihypertensive activities of Lisinopril. |
| Hydroflumethiazide | Dihydroergotamine may decrease the antihypertensive activities of Hydroflumethiazide. |
| Cryptenamine | Dihydroergotamine may decrease the antihypertensive activities of Cryptenamine. |
| Perindopril | Dihydroergotamine may decrease the antihypertensive activities of Perindopril. |
| Candesartan cilexetil | Dihydroergotamine may decrease the antihypertensive activities of Candesartan cilexetil. |
| Eprosartan | Dihydroergotamine may decrease the antihypertensive activities of Eprosartan. |
| Chlorothiazide | Dihydroergotamine may decrease the antihypertensive activities of Chlorothiazide. |
| Quinapril | Dihydroergotamine may decrease the antihypertensive activities of Quinapril. |
| Telmisartan | Dihydroergotamine may decrease the antihypertensive activities of Telmisartan. |
| Hydrochlorothiazide | Dihydroergotamine may decrease the antihypertensive activities of Hydrochlorothiazide. |
| Trichlormethiazide | Dihydroergotamine may decrease the antihypertensive activities of Trichlormethiazide. |
| Deserpidine | Dihydroergotamine may decrease the antihypertensive activities of Deserpidine. |
| Pentolinium | Dihydroergotamine may decrease the antihypertensive activities of Pentolinium. |
| Trimethaphan | Dihydroergotamine may decrease the antihypertensive activities of Trimethaphan. |
| Diazoxide | Dihydroergotamine may decrease the antihypertensive activities of Diazoxide. |
| Bretylium | Dihydroergotamine may decrease the antihypertensive activities of Bretylium. |
| Captopril | Dihydroergotamine may decrease the antihypertensive activities of Captopril. |
| Epoprostenol | Dihydroergotamine may decrease the antihypertensive activities of Epoprostenol. |
| Polythiazide | Dihydroergotamine may decrease the antihypertensive activities of Polythiazide. |
| Cilazapril | Dihydroergotamine may decrease the antihypertensive activities of Cilazapril. |
| Saprisartan | Dihydroergotamine may decrease the antihypertensive activities of Saprisartan. |
| Spirapril | Dihydroergotamine may decrease the antihypertensive activities of Spirapril. |
| Tienilic acid | Dihydroergotamine may decrease the antihypertensive activities of Tienilic acid. |
| Diethylnorspermine | Dihydroergotamine may decrease the antihypertensive activities of Diethylnorspermine. |
| Temocapril | Dihydroergotamine may decrease the antihypertensive activities of Temocapril. |
| Nicorandil | Dihydroergotamine may decrease the antihypertensive activities of Nicorandil. |
| Rauwolfia serpentina root | Dihydroergotamine may decrease the antihypertensive activities of Rauwolfia serpentina root. |
| Enalaprilat | Dihydroergotamine may decrease the antihypertensive activities of Enalaprilat. |
| Angiotensin 1-7 | Dihydroergotamine may decrease the antihypertensive activities of Angiotensin 1-7. |
| Imidapril | Dihydroergotamine may decrease the antihypertensive activities of Imidapril. |
| BQ-123 | Dihydroergotamine may decrease the antihypertensive activities of BQ-123. |
| Cicletanine | Dihydroergotamine may decrease the antihypertensive activities of Cicletanine. |
| Dihydralazine | Dihydroergotamine may decrease the antihypertensive activities of Dihydralazine. |
| Zofenopril | Dihydroergotamine may decrease the antihypertensive activities of Zofenopril. |
| Guanoxan | Dihydroergotamine may decrease the antihypertensive activities of Guanoxan. |
| Delapril | Dihydroergotamine may decrease the antihypertensive activities of Delapril. |
| Vincamine | Dihydroergotamine may decrease the antihypertensive activities of Vincamine. |
| Linsidomine | Dihydroergotamine may decrease the antihypertensive activities of Linsidomine. |
| Guanoxabenz | Dihydroergotamine may decrease the antihypertensive activities of Guanoxabenz. |
| Tolonidine | Dihydroergotamine may decrease the antihypertensive activities of Tolonidine. |
| Endralazine | Dihydroergotamine may decrease the antihypertensive activities of Endralazine. |
| Cadralazine | Dihydroergotamine may decrease the antihypertensive activities of Cadralazine. |
| Cyclopenthiazide | Dihydroergotamine may decrease the antihypertensive activities of Cyclopenthiazide. |
| Bietaserpine | Dihydroergotamine may decrease the antihypertensive activities of Bietaserpine. |
| Guanazodine | Dihydroergotamine may decrease the antihypertensive activities of Guanazodine. |
| Methoserpidine | Dihydroergotamine may decrease the antihypertensive activities of Methoserpidine. |
| Guanoclor | Dihydroergotamine may decrease the antihypertensive activities of Guanoclor. |
| Muzolimine | Dihydroergotamine may decrease the antihypertensive activities of Muzolimine. |
| Xipamide | Dihydroergotamine may decrease the antihypertensive activities of Xipamide. |
| Candesartan | Dihydroergotamine may decrease the antihypertensive activities of Candesartan. |
| Tocopherylquinone | Dihydroergotamine may decrease the antihypertensive activities of Tocopherylquinone. |
| Benazeprilat | Dihydroergotamine may decrease the antihypertensive activities of Benazeprilat. |
| Fosinoprilat | Dihydroergotamine may decrease the antihypertensive activities of Fosinoprilat. |
| Ramiprilat | Dihydroergotamine may decrease the antihypertensive activities of Ramiprilat. |
| Perindoprilat | Dihydroergotamine may decrease the antihypertensive activities of Perindoprilat. |
| Quinaprilat | Dihydroergotamine may decrease the antihypertensive activities of Quinaprilat. |
| Furosemide | Dihydroergotamine may decrease the antihypertensive activities of Furosemide. |
| Enalapril | Dihydroergotamine may decrease the antihypertensive activities of Enalapril. |
| Indapamide | Dihydroergotamine may decrease the antihypertensive activities of Indapamide. |
| Guanethidine | Dihydroergotamine may decrease the antihypertensive activities of Guanethidine. |
| Pinacidil | Dihydroergotamine may decrease the antihypertensive activities of Pinacidil. |
| Riociguat | Dihydroergotamine may decrease the antihypertensive activities of Riociguat. |
| Macitentan | Dihydroergotamine may decrease the antihypertensive activities of Macitentan. |
| Aliskiren | Dihydroergotamine may decrease the antihypertensive activities of Aliskiren. |
| Debrisoquine | Dihydroergotamine may decrease the antihypertensive activities of Debrisoquine. |
| Ambrisentan | Dihydroergotamine may decrease the antihypertensive activities of Ambrisentan. |
| Selexipag | Dihydroergotamine may decrease the antihypertensive activities of Selexipag. |
| Eplerenone | Dihydroergotamine may decrease the antihypertensive activities of Eplerenone. |
| Buthiazide | Dihydroergotamine may decrease the antihypertensive activities of Buthiazide. |
| Azilsartan medoxomil | Dihydroergotamine may decrease the antihypertensive activities of Azilsartan medoxomil. |
| Buprenorphine | Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dihydroergotamine. |
| Dronabinol | The serum concentration of Dronabinol can be increased when it is combined with Dihydroergotamine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Dihydroergotamine. |
| Hydrocodone | Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dihydroergotamine. |
| Magnesium sulfate | The therapeutic efficacy of Dihydroergotamine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Dihydroergotamine may increase the sedative activities of Metyrosine. |